Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
NMT Capital
AddedMar 19, 2024
UpdatedJun 28, 2026
NMT Capital

NMT Capital

Operating

Global private equity firm specializing in medical and tech investments.

Location
Quincy, MA, US
Founded
2023
Firm
Compare
Portfolio
Employees
Website

NMT Capital, also known as Nexus, is a globally oriented private equity firm managing investment funds based in Europe and the US. The firm focuses on investments in medical and technology sectors, with portfolio companies located in North America and Europe. Nexus invests across various stages of development, from early to late stages, including Series A, B, and C rounds, as well as convertible notes.

Notable portfolio companies include Kiora Pharmaceuticals, Proterra, and Zipit Wireless. Nexus is managed by principals with deep industry knowledge and experience, which also allows the firm to act as a consultant to global investment banks. This consulting role involves sourcing and evaluating private medical companies seeking acquirers, strategic partners, or growth capital. Nexus's investment philosophy emphasizes leveraging its expertise to add value beyond capital investment.

NMT Capital - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments7
Current Portfolio Count3
Total Portfolio Exits0

Top Investment Stages

Series C3 (42.9%)
Series B2 (28.6%)
Convertible Note1 (14.3%)
Series A1 (14.3%)

Stage Mix

Series C 43%Series B 29%Convertible Note 14%Series A 14%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Proterra logo

Proterra

Kiyatec logo

Kiyatec

Zipit Wireless logo

Zipit Wireless

Kiora Pharmaceuticals logo

Kiora Pharmaceuticals

NMT Capital - Similar Investment Firms

Nexus Capital Management logo

Nexus Capital Management

nexuslp.com

Nexus Venture Partners logo

Nexus Venture Partners

nexusvp.com

Merlin Nexus logo

Merlin Nexus

Natixis Private Equity logo

Natixis Private Equity

NMS Capital Services logo

NMS Capital Services

nms-capital.com

Nexus Group logo

Nexus Group

NKM Capital logo

NKM Capital

nkmcap.com

Northwest Technology Ventures logo

Northwest Technology Ventures

nwtechventures.com

NextEquity Partners logo

NextEquity Partners

nextequity.com

New Technology Ventures logo

New Technology Ventures

newtechvc.com

New Mountain Capital logo

New Mountain Capital

Norwest Mezzanine Partners logo

Norwest Mezzanine Partners

nmp.com

Nexxus Capital logo

Nexxus Capital

nexxuscapital.com

Nordic Capital logo

Nordic Capital

nordiccapital.com

Nexus Capital Partners logo

Nexus Capital Partners

NMT Capital - Classification

Also Known As
  • NMT Capital LTD
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
  • 523940Portfolio Management and Investment Advice
SIC
  • 6000Depository Institutions
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end